Čeština 
Slovenčina 
Română 
Deutsch ATUCARE
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
Atucare 1 x 90 hrd capsules
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atucare dutasteride/tamsulosin hydrochloride 0,5 mg/0,4 mg
THERAPEUTIC INDICATIONS
Fixed dose combination therapy (FDCT) is indicated for men taking both monotherapies with moderate-to-severe BPH/BPE-related LUTS (low urinary track symptoms) and enlarged prostate who are those at risk for disease progression.
DISPENSING AND REIMBURSEMENT
Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.
Mandatory information
